# Ablation Frontiers

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ablation-frontiers

- Industry: Medical Devices & Equipment
- Headquarters: Carlsbad, US
- Website: www.ablationfrontiers.com
- Total disclosed funding: $13M
- Latest round: Series C (May 29, 2007)
- Investors on record: 7

## About

Ablation Frontiers specializes in developing innovative medical devices for the treatment of cardiac arrhythmias, focusing on enhancing patient outcomes through advanced technologies and solutions.Founded in 2004 and headquartered in Carlsbad, US, Ablation Frontiers develops medical solutions for cardiac arrhythmias. The company was acquired by Medtronic in January 2009 for USD 225 mn, consolidating its assets to enhance its product offerings. The acquisition also marked a pivotal moment in the company's strategy, integrating its innovative technologies into Medtronic's extensive portfolio of healthcare solutions.Ablation Frontiers focuses on advanced medical devices that treat cardiac arrhythmias, offering solutions that improve patient care and clinical outcomes. The company's key products include innovative ablation technologies that assist healthcare professionals in delivering more effective treatments for patients with complex heart conditions.Ablation Frontiers generates revenue through the sale of its medical devices to healthcare facilities, primarily hospitals specializing in cardiology. The revenue model is supported by partnerships with healthcare providers that facilitate the integration of their products into treatment protocols, enhancing both initial sales and ongoing support services.Following its acquisition by Medtronic, Ablation Frontiers will leverage the resources and expertise of its parent company to expand its product line and enter new geographic markets. The latest round of funding, marked by the acquisition in January 2009 for USD 225 mn, will support the development of new ablation technologies aimed at treating a wider range of cardiac conditions, as well as facilitating entry into markets in Europe and Asia-Pacific by 2011.

## Funding rounds

- Series C, May 29, 2007, $13M — Versant Ventures, Aberdare Ventures, Novartis Venture Fund, Hexagon Investments, Trellis Health Ventures, Affinity Ventures, FirstMark Capital

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series C
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C
- Hexagon Investments (https://capitalatlas.ai/funds/hexagon-investments) — Series C
- Trellis Health Ventures (https://capitalatlas.ai/funds/trellis-health-ventures) — Series C
- Affinity Ventures — Series C
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series C